Article Text

Download PDFPDF
Clinical round-up
  1. Sophie Herbert1,
  2. Emily Chung2
  1. 1 Genitourinary Medicine, Ashwood Centre, Kettering, UK
  2. 2 Sexual Health and HIV, Mortimer Market Centre, London, UK
  1. Correspondence to Dr Sophie Herbert, Genitourinary Medicine, Ashwood Centre, Kettering WC1E 6JB, UK; sophieherbert{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

HBV vaccination in HIV-positive, HBVcAb-positive patients

Morsica et al 1 looked at 25 HIV-positive patients with isolated antibodies to hepatitis B core antigen (HBVcAb). The 25 patients, 80% male and 50% intravenous drug users, were tested at baseline and then vaccinated for hepatitis B and their response was monitored. Those with hepatitis B surface antibody <100 IU/L continued to have the full vaccination course with subsequent vaccines at weeks 5 and 24. Antibody titres were measured for all patients at baseline, and at 4 (postvaccination) 24 and 48 weeks. In addition hepatitis B virus (HBV) DNA quantification was also taken at these time points and hepatitis C antibody status was measured.

Their results show that 6/25 (24%) developed an antibody response and 4/6 had anti-HBs levels of >100 IU/L. Of the 19 remaining patients, 10 (52.6%) developed adequate immunity (>10 IU/L) after the third vaccine dose. Occult HBV infection was seen in four out of six patients who developed an antibody response after one vaccine, in two out of ten patients with …

View Full Text


  • Handling editor Jackie A Cassell

  • Contributors SH chose the papers and wrote the manuscript. EC edited and advised.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.